INNV vs. ADUS, TDOC, NHC, AHCO, VRDN, GRAL, AVAH, CDNA, FTRE, and PNTG
Should you be buying InnovAge stock or one of its competitors? The main competitors of InnovAge include Addus HomeCare (ADUS), Teladoc Health (TDOC), National HealthCare (NHC), AdaptHealth (AHCO), Viridian Therapeutics (VRDN), Grail (GRAL), Aveanna Healthcare (AVAH), CareDx (CDNA), Fortrea (FTRE), and The Pennant Group (PNTG). These companies are all part of the "healthcare" industry.
InnovAge vs.
Addus HomeCare (NASDAQ:ADUS) and InnovAge (NASDAQ:INNV) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.
Addus HomeCare received 329 more outperform votes than InnovAge when rated by MarketBeat users. Likewise, 68.83% of users gave Addus HomeCare an outperform vote while only 0.00% of users gave InnovAge an outperform vote.
95.3% of Addus HomeCare shares are owned by institutional investors. Comparatively, 12.3% of InnovAge shares are owned by institutional investors. 4.6% of Addus HomeCare shares are owned by company insiders. Comparatively, 1.4% of InnovAge shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Addus HomeCare has a net margin of 6.50% compared to InnovAge's net margin of -3.19%. Addus HomeCare's return on equity of 9.62% beat InnovAge's return on equity.
Addus HomeCare has higher revenue and earnings than InnovAge. InnovAge is trading at a lower price-to-earnings ratio than Addus HomeCare, indicating that it is currently the more affordable of the two stocks.
Addus HomeCare currently has a consensus price target of $132.78, suggesting a potential upside of 34.21%. InnovAge has a consensus price target of $5.00, suggesting a potential upside of 67.79%. Given InnovAge's higher possible upside, analysts plainly believe InnovAge is more favorable than Addus HomeCare.
Addus HomeCare has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, InnovAge has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500.
In the previous week, Addus HomeCare had 4 more articles in the media than InnovAge. MarketBeat recorded 4 mentions for Addus HomeCare and 0 mentions for InnovAge. InnovAge's average media sentiment score of 1.87 beat Addus HomeCare's score of 1.39 indicating that InnovAge is being referred to more favorably in the news media.
Summary
Addus HomeCare beats InnovAge on 17 of the 19 factors compared between the two stocks.
Get InnovAge News Delivered to You Automatically
Sign up to receive the latest news and ratings for INNV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
InnovAge Competitors List
Related Companies and Tools
This page (NASDAQ:INNV) was last updated on 4/1/2025 by MarketBeat.com Staff
